|Bid||14.73 x 4000|
|Ask||14.78 x 1000|
|Day's Range||13.75 - 14.81|
|52 Week Range||4.96 - 19.32|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.00|
Vertex's (VRTX) APOL1 inhibitor, VX-147, led to a significant reduction in protein in urine in a phase II study in APOL1-mediated FSGS, a severe kidney disorder.
NEW YORK, December 02, 2021--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to six newly-hired, non-executive employees.
AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.